Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria Initial results for odronextamab in first ...
FREDERICK, Md., Nov. 05, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that ...
HealthDay on MSN23h
ASH: Complications Common With Controlled Ovarian Hyperstimulation in Sickle Cell AnemiaMany individuals with sickle cell anemia undergoing controlled ovarian hyperstimulation (COH) with oocyte cryopreservation ...
HealthDay on MSN23h
ASH: GLP-1 RA Use Tied to Lower Rate of Venous Thromboembolism in DiabetesFor patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...
Many individuals with sickle cell anemia undergoing controlled ovarian hyperstimulation (COH) with oocyte cryopreservation ...
GSK's phase 3 trial shows Blenrep combined with BorDex improves overall survival in relapsed multiple myeloma.
Routine blood draws during a doctor's visit can reveal disorders or diseases and as the number of patient caseloads inches ...
San Francisco–based Ossium Health has carried out three transplants for cancer patients using stem cells from deceased donors ...
Regeneron (REGN) Pharmaceuticals announced new and updated data from its hematology pipeline will be shared across 23 abstracts at the American Society of Hematology, ASH, 2024 Annual Meeting, taking ...
" I’m honored to join Innate Pharma at such a pivotal moment in its evolution,”said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “ We achieved notable regul ...
Research findings from Sylvester Comprehensive Cancer Center and the Miller School of Medicine at the University of Miami ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback